Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2negative Breast Cancers

被引：0
|
作者：
Luzhna, Lidiya
Chia, Stephen
Pauls, Mehrnoosh
Levasseur, Nathalie
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-15-04
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
    Pronzato, Paolo
    FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384
  • [42] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    BREAST CARE, 2024, 19 (01) : 27 - 33
  • [43] Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?
    Yepes, Monica Maria
    Romilly, Ada Pat
    Collado-Mesa, Fernando
    Net, Jose Miguel
    Kiszonas, Richard
    Arheart, Kristopher L.
    Young, Daniel
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (01) : 117 - 123
  • [44] A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤5).
    Abu-Khalaf, Maysa M.
    Mougalian, Sarah Schellhorn
    Sanft, Tara Beth
    Hofstatter, Erin Wysong
    Chung, Gina G.
    Adelson, Kerin B.
    Silber, Andrea
    Brandt, Debra S.
    Bober-Sorcinelli, Kathleen E.
    Fishbach, Neal
    Kidwai, Wajih Zaheer
    Sabbath, Kert D.
    DiGiovanna, Michael
    Sikov, William M.
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?
    Monica Maria Yepes
    Ada Pat Romilly
    Fernando Collado-Mesa
    Jose Miguel Net
    Richard Kiszonas
    Kristopher L. Arheart
    Daniel Young
    Stefan Glück
    Breast Cancer Research and Treatment, 2014, 148 : 117 - 123
  • [46] Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer.
    Crager, Michael
    Wijayawardana, Sameera R.
    Gruver, Aaron M.
    Blacklock, Andrea
    Baehner, Frederick L.
    Russell, Christy
    Sapunar, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Caitlin Taylor
    Jane Meisel
    Aimee J. Foreman
    Christy Russell
    Dipankar Bandyopadhyay
    Xiaoyan Deng
    Lisa Floyd
    Amelia Zelnak
    Harry Bear
    Ruth O’Regan
    Breast Cancer Research and Treatment, 2023, 199 : 91 - 98
  • [48] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Taylor, Caitlin
    Meisel, Jane
    Foreman, Aimee J.
    Russell, Christy
    Bandyopadhyay, Dipankar
    Deng, Xiaoyan
    Floyd, Lisa
    Zelnak, Amelia
    Bear, Harry
    O'Regan, Ruth
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 91 - 98
  • [49] Ki-67 Proliferative Index in Estrogen Receptor-Positive/HER2-Neu Negative Early Breast Cancer Predicts Oncotype DX Recurrence Score
    Kelly, C.
    Saad, R. S.
    Nofech-Mozes, S.
    Kahn, H.
    Zubovits, J.
    Wong, J.
    Hanna, W. M.
    LABORATORY INVESTIGATION, 2010, 90 : 55A - 55A
  • [50] Ki-67 Proliferative Index in Estrogen Receptor-Positive/HER2-Neu Negative Early Breast Cancer Predicts Oncotype DX Recurrence Score
    Kelly, C.
    Saad, R. S.
    Nofech-Mozes, S.
    Kahn, H.
    Zubovits, J.
    Wong, J.
    Hanna, W. M.
    MODERN PATHOLOGY, 2010, 23 : 55A - 55A
12345